This inventor holds 41 USPTO granted patents and 22 published patent applications, plus 11 CIPO patents and 17 EPO patents, primarily in Antibody Engineering. Top assignees: Ucb Biopharma Sprl, Ucb Pharma, S.a., Ucbbiopharma Srl. Active years: 2011-2026.
Location History:
- Surrey, GB (2013)
- Berkshire, GB (2013 - 2022)
- Slough, GB (2011 - 2024)
Company Filing History:
15 out of 138 
13 out of 180 
11 out of 129 
Years Active: 2011-2026
Areas of Expertise:
Title: Ralph Adams - Innovator in Antibody Development
Introduction
Ralph Adams, based in Slough, GB, is a distinguished inventor with an impressive portfolio of 37 patents. His work primarily focuses on the development of innovative antibodies, addressing significant medical challenges.
Latest Patents
Among Ralph's latest innovations are two notable patents. The first patent pertains to "Antibodies of the class IGG4." This invention details an antibody comprising at least one heavy chain with a C1 domain and a hinge region. Key features include the substitution of an inter-chain cysteine at position 127 with another amino acid and the modification of amino acids in the upper hinge region to include cysteine.
The second patent, "Anti-IgE antibodies," relates to improved anti-IgE antibodies and antigen binding agents. This invention is significant for treating disorders caused by IgE, such as allergic and certain autoimmune responses. It focuses on enhanced affinity for IgE and improved interactions with the Cε2 domain of IgE, which could revolutionize treatments for IgE-mediated disorders.
Career Highlights
Ralph has made substantial contributions in the biopharmaceutical field, having worked with leading companies such as UCB Biopharma Sprl and UCB Pharma, S.A. His expertise in antibody science has positioned him as a key figure in the development of therapeutic strategies to combat IgE-related conditions.
Collaborations
Throughout his career, Ralph has collaborated with notable professionals like Andrew George Popplewell and Stephen Edward Rapecki. These collaborations have further enriched his research and development efforts, leading to significant advancements in antibody-based therapies.
Conclusion
Ralph Adams exemplifies innovation in biomedicine through his extensive patent portfolio and collaborative spirit. His contributions to antibody development not only demonstrate his prowess as an inventor but also the potential impact of his work on treating immunity-related disorders. As he continues to push the boundaries of scientific understanding, the medical community can look forward to advancements stemming from his research.